Arnica

Metadata

Approved Indications

German Commission E (1984 Positive Monograph)

External use only for:

• Injury and accident consequences: bruises, sprains, contusions, fracture-associated edema
• Rheumatic muscle and joint pain
• Inflammation of the mouth and throat (as mouthwash/gargle)
• Furuncles
• Inflammation caused by insect bites
• Superficial phlebitis

ESCOP (2019 Monograph)

• Treatment of bruises, sprains, and inflammation caused by insect bites
• Gingivitis and aphthous ulcers (as mouthwash)
• Symptomatic treatment of rheumatic complaints and muscular pain

EMA/HMPC

• Traditional use status for:
  • Treatment of bruises, sprains, and localized muscular pain (cutaneous use)
• Based on long-standing use (>=30 years)

Agreement/Disagreement Among Authorities

• Agreement: All authorities restrict to external/topical use only; all recognize bruises, sprains, and musculoskeletal pain
• Commission E is broadest: Includes phlebitis, furuncles, insect bites, and oral/throat inflammation
• EMA is most conservative: Only “traditional use” status; does not recognize OA indication
• ESCOP is intermediate: Includes rheumatic complaints and oral indications

Conditions Treated

Primary (Evidence-Supported, Topical)

• Bruising and ecchymosis (post-traumatic, post-surgical)
• Sprains and contusions
• Osteoarthritis (topical gel/cream — hand OA best studied)
• Muscular pain and stiffness

Secondary (Traditional/Supported by Lesser Evidence)

• Post-surgical swelling
• Superficial phlebitis
• Insect bite inflammation
• Gingivitis (as mouthwash, diluted tincture)

NOT Indicated

• Internal/oral use — TOXIC. Helenalin is cardiotoxic and can cause fatal organ failure if ingested in pharmacological doses
• Note: Homeopathic preparations (extreme dilutions, e.g., 6C, 30C) are a separate framework and fall outside this review

Mechanism of Action

Key Active Compounds

• Helenalin (sesquiterpene lactone) — primary active compound; potent anti-inflammatory
• 11,13-Dihydrohelenalin and its esters
• Helenalin acetate and helenalin methacrylate
• Flavonoids (including hispidulin, patuletin, spinacetin glycosides)
• Essential oils and carotenoids

Pharmacological Mechanisms

1. NF-kB inhibition: Helenalin alkylates the p65 subunit of NF-kB, preventing its activation and nuclear translocation. This is a potent, well-characterized mechanism — NF-kB is a master regulator of inflammatory gene expression controlling TNF-alpha, IL-1, IL-6, COX-2, and iNOS [Source: Lyss et al., 1998]
2. NF-AT inhibition: Sesquiterpene lactones also inhibit the nuclear factor of activated T-cells (NF-AT), another key transcription factor in immune activation
3. Anti-edema effects: Reduces vascular permeability and fluid extravasation at injury sites
4. Antimicrobial activity: Demonstrated in vitro against various bacteria and fungi
5. Antioxidant effects: Scavenging of reactive oxygen species
6. Anti-platelet effects: In vitro inhibition of platelet aggregation

European Pharmacopoeia Quality Standards

• Minimum sesquiterpene lactone content: 0.4% (some sources cite 0.7% m/m total sesquiterpene lactones)
• Standardization to helenalin and dihydrohelenalin content is standard practice for quality extracts

Clinical Evidence Summary

Key Individual Trials

Osteoarthritis

Bruising and Post-Surgical Swelling

• Multiple smaller studies with mixed results for post-surgical bruising
• Iannitti et al. (2014): Systematic review found evidence for efficacy in treatment of pain, swelling, and bruises, but noted heterogeneity in preparations and study quality
• Post-rhinoplasty, post-facelift, and post-arthroscopy studies have shown variable results [CONTESTED — some positive, some null findings; preparation type and concentration likely explain heterogeneity]

Varicose Veins

• Controlled studies have demonstrated benefit for symptoms of varicose veins (pain, heaviness, edema) with topical arnica preparations

Limitations of Evidence

• The Widrig 2007 trial is the single strongest piece of clinical evidence
• Many studies use different preparations (tinctures, gels, creams) at different concentrations, making cross-study comparison difficult
• Post-surgical bruising evidence is mixed, possibly because arnica works better for musculoskeletal inflammation than for simple subcutaneous hematoma
• Homeopathic arnica studies (extreme dilutions) are a different category entirely and should not be conflated with phytotherapeutic evidence

European vs. US/Anglophone Consensus

Key distinction: In the US, “arnica” is largely synonymous with homeopathic arnica (Arnicare, etc.), which uses extreme dilutions and a different therapeutic framework. European phytotherapy uses pharmacologically active concentrations of arnica extract in topical preparations. These are fundamentally different products.

Safety Profile

CRITICAL SAFETY WARNING

Arnica is TOXIC when taken internally. Helenalin is a potent cardiotoxin and cytotoxin. Ingestion of pharmacologically relevant amounts of arnica can cause:

• Tachycardia and cardiac arrest
• Severe gastroenteritis
• Organ failure
• Death

Internal use is absolutely contraindicated except in homeopathic dilutions (which contain negligible amounts of active compound).

Contraindications (Topical Use)

• Known allergy to Asteraceae/Compositae family (chamomile, ragweed, marigold, chrysanthemum, echinacea, etc.)
• Broken or damaged skin: Do not apply to open wounds, abrasions, or ulcerated skin
• Mucous membranes: Only as diluted mouthwash for oral indications; never undiluted
• Prolonged use: Avoid extended continuous application (risk of contact dermatitis increases)

Drug Interactions (Topical)

• Minimal systemic absorption when applied topically to intact skin
• Theoretical interaction with anticoagulants if applied to large areas or damaged skin (unlikely in practice)
• No significant drug interactions reported for properly formulated topical preparations

Side Effects

• Contact dermatitis: The most important adverse effect; caused by sesquiterpene lactones (helenalin, helenalin acetate, helenalin methacrylate) which are the same compounds responsible for efficacy
• Risk is elevated in individuals with pre-existing Compositae sensitivity
• Prevalence of sensitization: ~1-2% in general population; higher in those with occupational plant exposure
• Eczematous reactions possible with prolonged use
• Local irritation, redness, or itching in sensitive individuals

Pregnancy and Lactation

• Pregnancy: Topical use on intact skin is generally considered acceptable in short courses. Internal use is absolutely contraindicated
• Lactation: Avoid application near the breast; do not allow infant contact with treated skin areas

Clinical Dosage

Recommended Forms and Doses

Key Dosing Principles

1. External/topical use ONLY — never internal
2. Do not apply to broken skin or open wounds
3. Limit duration: Avoid continuous use beyond 2-3 weeks without a break
4. Test for sensitivity: Consider a small test patch in Compositae-sensitive individuals
5. Standardized preparations preferred: Products standardized to sesquiterpene lactone content provide more reliable dosing

Key European Products

• A. Vogel Arnica Gel — used in the Knuesel knee OA study
• Kneipp Arnika Salbe (Germany)
• Weleda Arnika range (cream, massage oil) — widely available in European pharmacies
• Doc Arnika (Germany) — pharmacy-registered product
• First “traditional herbal medicine” registered in the UK under MHRA regulations

Sources

• Widrig R et al. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int. 2007;27(6):585-591.
• Knuesel O et al. Arnica montana gel in osteoarthritis of the knee: an open, multicenter clinical trial. Adv Ther. 2002;19(5):209-218.
• Lyss G et al. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB. Biol Chem. 1998;379(2):159-165.
• Iannitti T et al. Systematic review on the efficacy of topical Arnica montana for the treatment of pain, swelling and bruises. J Pharm Pharmacol. 2014.
• EMA/HMPC. Assessment report on Arnica montana L., flos. European Medicines Agency.
• EMA/HMPC. Community herbal monograph on Arnica montana L., flos.
• ESCOP. Arnicae flos (Arnica flower) Monograph. 2019.
• German Commission E. Arnica Monograph. 1984.

Connections

• Compare with Comfrey — both topical anti-inflammatories; comfrey has stronger OA evidence
• Compare with Capsicum — alternative topical approach with different mechanism